A recent False Claims Act (FCA) ruling out of Tennessee offers a pointed reminder for hospitals and health systems: physician contracts that appear compliant on paper can still create serious enforcement risk if the economics tell a different story. In denying motions to dismiss FCA claims involving Erlanger Health System (Erlanger), the federal court allowed allegations regarding physician compensation to proceed, reinforcing that these arrangements remain fertile ground for qui tam relators and the Department of Justice (DOJ). For organizations contracting with physicians, the message is clear: independent fair market value (FMV) review, rigorous documentation, regular auditing, and meaningful board oversight are essential defenses, not mere optional safeguards. 

FCA Primer

The FCA is the federal government’s most powerful weapon for combating healthcare fraud, and physician compensation cases can become very costly very quickly. Under the FCA, a provider that knowingly submits, or causes the submission of, false claims for payment to a federal healthcare program (e.g., Medicare, Medicaid, or TRICARE) faces treble damages and steep penalties of $14,308 to $28,619 per claim. Also, the FCA’s qui tam provision empowers private whistleblowers (called relators) to file suit on behalf of the government and to share in any recovery. Once a relator files suit, the DOJ may elect to intervene in some or all of the relator’s claims, transforming a private whistleblower case into a government-backed enforcement action when it does so.

The FCA presents substantial risk for hospitals and health systems that employ or contract with physicians because violations of the physician self-referral law (known as the Stark Law) or the Anti-Kickback Statute (AKS) can convert subsequent federal healthcare program claims into false claims, exposing providers to treble damages and costly per-claim penalties.

Erlanger Health System Case

A recent case involving Erlanger Health System in Tennessee illustrates the severity of these risks and provides useful guidance for compliance professionals. Erlanger’s former Chief Compliance Officer and former Chief Financial Officer filed this qui tam action alleging that Erlanger offered excessive compensation and financial incentives to induce referrals from employed and non-employed physicians. The United States partially intervened with respect to claims that Erlanger violated the FCA by submitting, or causing the submission of, Medicare claims for services referred by physicians whose employment arrangements with Erlanger allegedly violated the Stark Law.

Specifically, the DOJ’s complaint in intervention alleges that Erlanger paid certain physicians compensation equal to two to three times the median salary for their specialties, with individual compensation packages exceeding the physicians’ professional collections. Erlanger allegedly tolerated these losses because it tracked, and based the physicians’ compensation upon, millions of dollars in “downstream revenue,” such as inpatient hospital stays referred by the physicians and the facility fees, laboratory tests, and other hospital charges ancillary to the physicians’ services.

The relators’ broader complaint, which includes non-intervened claims, alleges Stark Law and AKS violations involving Erlanger’s arrangements with non-employed physicians. According to the relators, Erlanger made pass through payments to a medical school to fund faculty salaries of non-employed physicians who referred services to Erlanger. The relators also claim that Erlanger paid non-employed physicians for non-existent call coverage and unnecessary medical director services, paid non-employed physicians in excess of fair market value to manage an outpatient surgery center, and provided remuneration through free or low-cost IT support and nurse practitioner services.

Key Risk Areas Highlighted by the Complaints

Compensation Exceeding Fair Market Value

The complaints allege that Erlanger’s total physician compensation — including base salary, medical director stipends, academic payments, uncapped call coverage, sign-on bonuses, and productivity incentives — substantially exceeded FMV when viewed in the aggregate. The DOJ further alleges that independent FMV analyses failed to account for the physicians’ actual total compensation, creating a gap between paper compliance and economic reality.

Referral Tracking and Downstream Revenue

The complaints allege that Erlanger tracked referral “leakage” and contribution margins tied to individual physicians and used projected downstream hospital revenue — allegedly as high as $21 million for a single physician — to justify compensation. Under the Stark Law, compensation that is determined by the volume or value of referrals cannot satisfy the bona fide employment exception that would otherwise shield an arrangement from Stark liability.

wRVU/Productivity Incentives and Coding Concerns

The DOJ alleges that Erlanger commissioned outside coding reviews that found that some employed physicians were inaccurately billing for evaluating or managing patients’ health. According to the DOJ, such “E/M coding” inaccuracies inflated work relative value units (wRVUs), which in turn increased the physicians’ uncapped productivity bonuses. Hospitals that rely on uncapped wRVU-based incentives face heightened risk when they do not independently verify coding accuracy.

Medical Director, Academic, and Call Coverage Payments

The complaints allege that Erlanger’s medical director and academic stipends lacked documentation of services actually performed and that call coverage payments were uncapped. These payment categories can serve as vehicles for above-FMV compensation if they are not tied to documented, commercially reasonable services. Rigorous documentation is critical because the Stark Law exception and the AKS safe harbor for personal service arrangements require that the aggregate services covered by the arrangement be reasonable, necessary, and supported by a legitimate business purpose.

Pass-Through Payments and Third-Party Arrangements

The relators allege that Erlanger routed payments through a medical school to fund compensation for physician groups without adequate FMV support. Pass-through funding arrangements can create the same Stark Law and AKS risks as direct compensation when those funds are intended to benefit referring physicians. Accordingly, hospitals and health systems should require the same level of scrutiny for indirect compensation arrangements as they do for direct compensation.

Compliance Governance Failures

Perhaps most troubling, the complaints allege that Erlanger weakened its compliance infrastructure by eliminating the Chief Compliance Officer position, resisted independent review of physician compensation, and relaxed oversight after the expiration of a Corporate Integrity Agreement that Erlanger entered into with the Department of Health and Human Services Office of Inspector General in connection with a prior settlement of FCA allegations premised on Stark Law violations. Effective compliance infrastructure is the first line of defense, and compliance governance failures such as these could support an inference of knowledge or deliberate ignorance of the compliance risk that is needed to support FCA claims.

Lessons and Best Practices for Hospitals and Health Systems

• Evaluate total compensation holistically. FMV and commercial reasonableness analyses must account for all components — base salary, medical director pay, academic stipends, call coverage, bonuses, and productivity incentives — not each element in isolation.
• Separate referral analytics from compensation decisions. Never use downstream revenue projections, leakage reports, or contribution margin data to set or justify physician pay.
• Audit actual compensation against benchmarks. Conduct regular hindsight reviews comparing actual total compensation to contracted assumptions and recognized survey benchmarks. Investigate outliers promptly.
• Document services performed. Require contemporaneous time logs and deliverable records for medical director duties, academic responsibilities, and call coverage.
• Validate wRVU productivity models. Independently audit coding accuracy, medical necessity, and documentation quality before implementing or continuing uncapped productivity incentives.
• Scrutinize pass-through and indirect arrangements. Apply the same FMV discipline to payments routed through academic institutions or management companies as to direct physician contracts.
• Maintain robust compliance governance. Preserve an independent compliance function with board-level reporting, escalation authority, and the resources to conduct proactive reviews. Never weaken oversight structures after a Corporate Integrity Agreement concludes.
• Maintain complete contracting files. Keep a centralized file for every physician arrangement documenting the executed agreement, FMV opinion, commercial reasonableness assessment, board approval, and any amendments.
• Act on red flags. When internal reviews or outside consultants identify compliance concerns, investigate them promptly and consider self-disclosure and refund obligations under the 60-day repayment rule.

Conclusion

The Erlanger case demonstrates that physician compensation arrangements can create significant FCA exposure even when contracts are supported by facially complaint documentation. The combination of qui tam whistleblower incentives, strict liability under the Stark Law, and the FCA’s treble damages makes physician contracting a high-risk area for hospitals and health systems. Proactive compliance efforts are the most effective risk mitigation strategy, and that compliance must be tested against economic reality. Total compensation, referrals data, documentation of services, coding accuracy, and governance and compliance oversight all matter. Hospitals that discover potential overpayments or compliance deficiencies should consult experienced healthcare counsel promptly to evaluate self-disclosure, refund obligations, and corrective action.